Dr. Mukhtyar has received speaking fees (less than $10,000 each) from Schering-Plough and Menarini UK.
Health-related quality of life in patients with newly diagnosed antineutrophil cytoplasmic antibody–associated vasculitis
Article first published online: 29 JUN 2011
Copyright © 2011 by the American College of Rheumatology
Arthritis Care & Research
Volume 63, Issue 7, pages 1055–1061, July 2011
How to Cite
Walsh, M., Mukhtyar, C., Mahr, A., Herlyn, K., Luqmani, R., Merkel, P. A. and Jayne, D. R. W. (2011), Health-related quality of life in patients with newly diagnosed antineutrophil cytoplasmic antibody–associated vasculitis. Arthritis Care Res, 63: 1055–1061. doi: 10.1002/acr.20471
- Issue published online: 29 JUN 2011
- Article first published online: 29 JUN 2011
- Accepted manuscript online: 30 MAR 2011 10:50AM EST
- Manuscript Accepted: 9 MAR 2011
- Manuscript Received: 21 JUL 2010
- Canadian Institutes of Health Research
- Vasculitis Clinical Research Consortium
- National Institute of Arthritis and Musculoskeletal and Skin Diseases. Grant Number: U54AR057319
- National Center for Research Resources. Grant Number: U54RR019497
- Office of Rare Diseases Research
- US FDA. Grant Number: R01-FD003516-01
Antineutrophil cytoplasmic antibody–associated vasculitis (AAV) can present with a broad spectrum of signs and symptoms. The relative effects of different manifestations on health-related quality of life (HRQOL) are unknown.
We conducted an individual patient data meta-analysis of baseline Short Form 36 (SF-36) scores from 4 randomized controlled trials of patients with newly diagnosed AAV. We determined the associations between organ manifestations at trial entry and the SF-36 physical composite score (PCS) and mental composite score (MCS) using mixed-effects models adjusted for demographic factors. Associations with each of the 8 domains of the SF-36 were further explored using multivariate multiple regression.
SF-36 data were available from 346 patients. Older age (−0.11 points/year [95% confidence interval (95% CI) −0.21, −0.012]; P = 0.029) and neurologic involvement (−5.84 points; P < 0.001) at baseline were associated with lower PCS. Physical functioning scores were the most affected and older age scores (−0.25 points/year [95% CI −0.38, −0.11]; P < 0.001) and neurologic involvement (−8.48 points [95% CI −12.90, −4.06]; P < 0.001) had the largest effects. The MCS was negatively affected only by chest involvement (P = 0.027), but this effect was not exerted in any particular domain.
In patients with newly diagnosed AAV, HRQOL is complex and incompletely explained by their organ system manifestations.